Emergence Therapeutics licences Synaffix platform
Synaffix B.V. and Emergence Therapeutics AG have entered into a licensing agreement of up to $360m to find ADCs directed against target molecules from Emergence.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Abivax SA bags 49.2m to push ABX-464
/in News/by Thomas GabrielczykParis-based Abivax SA has cashed in 49.2m in an oversubscribed financing with top-tier US and European biotech investors.
BioEcho Life Sciences launches US subsidiary
/in News/by Thomas GabrielczykGerman nucleic acid extraction specialist BioEcho Life Sciences has opened a subsidiary in Boston to supply the huge US-american market.
Belgian researchers create extraembryonic mesoderm cells
/in News/by Thomas GabrielczykResearchers from KU Leuven for the first time have produced human cells able to mimic the molecular mechanisms of early human embryogenesis and related defects.
SARS-CoV-2 infection triggers chronic fatigue syndrome
/in News/by Thomas GabrielczykA small prospective study among mid-aged people has demonstrated that a mild SARS-CoV-2 infection triggers ME/CF in 50% of the study population.<button lang="en-GB" aria-description="Klicken, um Alternative zu verwenden"></button>
Danish Bactolife A/S grabs funding
/in News/by Thomas GabrielczykSwedish food and feed supplement specialist Bactolife A/S has received US$5m in funding from the Bill & Melinda Gates Foundation to address gastrointestinal infections.
Moderna launches patent dispute with BioNTech/Pfizer
/in News/by Thomas GabrielczykFor the second time within a short period of time, a competitor has sued the mRNA vaccine developer BioNtechPfizer for patent infringement.
Belgian eTheRNA raises 39m in Series B2 financing
/in News/by Thomas GabrielczykModerna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a 39m Series B2 financing in eTheRNA.
Kinarus announces CHF 20 million convertible bond issue
/in News/by Thomas GabrielczykKinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd.
Cancer: Western life style is a killer
/in News/by Thomas GabrielczykA study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.